Filings & corporate actions
77 results filed
CSVNext results · Q2 FY27
Expected 28 Oct 2026 – 13 Nov 2026
Estimate: filed 28–44 days after quarter end, last 5 times
Dividend
₹3.00 per share · last 11 Aug 2026
2026
- 11 AugdividendDividend · ₹3.00 per share-1.9%
- 7 AugresultsResults · Q1 FY27 · consolidated and standalone-5.0%NSE
- 9 JulshareholdingShareholding · 30 Jun 2026+3.8%NSE
- 19 MayresultsResults · Q4 FY26 · consolidated and standalone-2.9%NSE
- 6 AprshareholdingShareholding · 31 Mar 2026+4.6%NSE
- 22 JanresultsResults · Q3 FY26 · consolidated and standalone-3.9%NSE
- 8 JanshareholdingShareholding · 31 Dec 2025-1.6%NSE
Reaction to results · all yearsrose on day 0 in 31 of 75 CSV
| Quarter | Filed | Day 0 | +5D | +20D | Rel vol |
|---|---|---|---|---|---|
| Q1 FY27 | 7 Aug 2026 | -5.0% | -0.2% | +22.0% | 2.2× |
| Q4 FY26 | 19 May 2026 | -2.9% | +12.4% | +7.3% | 2.4× |
| Q3 FY26 | 22 Jan 2026 | -3.9% | -7.7% | -4.8% | 0.5× |
| Q2 FY26 | 12 Nov 2025 | -5.1% | -11.2% | -13.6% | 3.8× |
| Q1 FY26 | 29 Jul 2025 | -1.7% | -6.0% | -8.2% | 1.3× |
| Q4 FY25 | 23 May 2025 | +0.8% | +1.1% | -5.4% | 0.3× |
| Q3 FY25 | 12 Feb 2025 | +2.5% | +4.3% | -5.5% | 2.4× |
| Q2 FY25 | 13 Nov 2024 | -6.1% | -8.4% | -11.1% | 2.4× |
| Q1 FY25 | 8 Aug 2024 | -1.7% | +10.3% | +34.7% | 3.9× |
| Q4 FY24 | 16 May 2024 | +2.5% | -4.1% | +5.4% | 1.4× |
| Q3 FY24 | 7 Feb 2024 | +7.0% | -4.7% | -3.0% | 11.3× |
| Q2 FY24 | 7 Nov 2023 | -2.8% | +4.4% | +8.8% | 1.3× |
| Q1 FY24 | 10 Aug 2023 | +0.7% | +6.7% | +37.1% | 1.6× |
| Q4 FY23 | 26 May 2023 | +2.0% | +27.5% | +28.9% | 0.9× |
| Q3 FY23 | 10 Feb 2023 | +5.7% | +10.0% | -14.9% | 2.0× |
| Q2 FY23 | 12 Nov 2022 | -11.2% | -21.3% | -9.4% | 3.3× |
| Q1 FY23 | 10 Aug 2022 | -1.8% | -1.6% | -7.6% | 1.7× |
| Q4 FY22 | 30 May 2022 | +1.9% | +1.7% | -9.5% | 0.6× |
| Q3 FY22 | 3 Feb 2022 | -3.3% | -7.7% | -15.8% | 2.0× |
| Q2 FY22 | 28 Oct 2021 | -2.5% | +5.9% | +22.4% | 1.4× |
| Q1 FY22 | 6 Aug 2021 | 0.0% | -6.1% | -2.5% | 3.4× |
| Q4 FY21 | 28 May 2021 | -5.0% | -2.2% | +1.9% | 1.1× |
| Q3 FY21 | 22 Jan 2021 | -5.0% | -6.1% | -1.8% | 0.9× |
| Q2 FY21 | 30 Oct 2020 | +5.0% | -0.2% | +3.6% | 1.8× |
| Q1 FY21 | 12 Aug 2020 | +5.0% | +10.7% | +3.8% | 0.6× |
| Q4 FY20 | 1 Jul 2020 | +5.0% | +9.5% | +36.7% | 0.6× |
| Q3 FY20 | 31 Jan 2020 | -2.0% | -6.2% | -25.4% | 1.2× |
| Q2 FY20 | 25 Oct 2019 | 0.0% | +19.1% | +35.2% | 1.1× |
| Q1 FY20 | 9 Aug 2019 | -1.1% | -11.8% | -6.5% | 1.8× |
| Q4 FY19 | 26 Jun 2019 | +2.3% | +8.7% | -3.3% | 1.5× |
| Q3 FY19 | 24 Jan 2019 | -0.2% | +5.3% | -10.6% | 0.8× |
| Q2 FY19 | 20 Nov 2018 | +3.4% | +1.0% | +17.7% | 0.9× |
| Q1 FY19 | 28 Aug 2018 | -3.2% | -5.5% | -23.2% | 0.5× |
| Q4 FY18 | 28 Jun 2018 | +3.4% | +3.1% | -0.4% | 0.5× |
| Q3 FY18 | 16 Mar 2018 | -4.3% | -13.1% | +11.9% | 0.5× |
| Q2 FY18 | 26 Dec 2017 | +0.7% | +4.5% | +12.2% | 1.4× |
| Q1 FY18 | 22 Sept 2017 | -5.5% | -3.6% | -3.5% | 0.9× |
| Q4 FY17 | 27 May 2017 | -6.6% | +0.1% | -2.5% | 0.8× |
| Q3 FY17 | 9 Feb 2017 | +0.7% | +0.3% | +3.8% | 1.5× |
| Q2 FY17 | 16 Nov 2016 | -0.6% | -4.3% | +14.1% | 0.3× |
| Q1 FY17 | 12 Aug 2016 | -3.8% | +11.8% | +19.2% | 0.6× |
| Q4 FY16 | 31 May 2016 | +3.7% | +2.6% | +3.4% | 2.8× |
| Q3 FY16 | 13 Feb 2016 | +9.1% | +4.6% | +16.3% | 0.8× |
| Q2 FY16 | 7 Nov 2015 | +15.4% | +15.3% | +37.8% | 4.5× |
| Q1 FY16 | 14 Aug 2015 | -3.7% | -14.6% | -12.6% | 0.5× |
| Q4 FY15 | 30 May 2015 | +3.9% | -4.0% | -5.0% | 1.2× |
| Q3 FY15 | 20 Feb 2015 | -0.1% | -7.8% | +3.3% | 0.7× |
| Q2 FY15 | 21 Nov 2014 | -2.0% | -2.5% | -13.4% | 0.5× |
| Q1 FY15 | 20 Aug 2014 | +11.9% | +34.3% | +48.0% | 5.9× |
| Q4 FY14 | 9 Jun 2014 | +3.9% | -2.6% | +7.7% | 4.0× |
| Q3 FY14 | 20 Feb 2014 | -1.6% | +6.2% | -5.8% | 0.6× |
| Q2 FY14 | 22 Nov 2013 | +2.7% | +2.7% | -0.5% | 1.7× |
| Q1 FY14 | 20 Aug 2013 | +3.9% | -1.1% | +2.8% | 0.4× |
| Q4 FY13 | 24 Jun 2013 | +6.9% | +8.5% | +15.4% | 1.5× |
| Q3 FY13 | 15 Feb 2013 | -5.9% | +2.2% | -6.2% | 2.3× |
| Q2 FY13 | 12 Nov 2012 | +3.5% | +4.0% | +5.4% | 1.0× |
| Q1 FY13 | 16 Aug 2012 | -0.9% | 0.0% | +29.0% | 0.7× |
| Q4 FY12 | 16 May 2012 | 0.0% | -6.3% | -5.0% | 0.4× |
| Q3 FY12 | 13 Feb 2012 | -2.6% | -4.5% | -16.2% | 0.4× |
| Q2 FY12 | 18 Nov 2011 | -3.2% | -2.4% | -16.8% | 0.3× |
| Q1 FY12 | 30 Jul 2011 | +0.2% | -14.9% | -11.4% | 0.7× |
| Q4 FY11 | 17 May 2011 | -0.9% | -0.5% | +7.4% | 0.5× |
| Q3 FY11 | 19 Feb 2011 | -4.5% | -15.5% | -13.0% | 0.3× |
| Q2 FY11 | 15 Nov 2010 | -5.9% | -5.9% | -9.0% | 1.0× |
| Q1 FY11 | 10 Aug 2010 | -2.0% | -4.6% | -4.0% | 0.7× |
| Q4 FY10 | 14 May 2010 | -5.1% | -12.0% | -4.1% | 1.2× |
| Q3 FY10 | 29 Jan 2010 | +5.1% | -1.6% | +0.2% | 0.7× |
| Q2 FY10 | 31 Oct 2009 | +5.0% | +15.9% | +41.8% | 9.5× |
| Q1 FY10 | 29 Jul 2009 | -2.0% | -8.5% | +18.1% | 0.9× |
| Q4 FY09 | 30 Jun 2009 | +0.5% | -4.5% | +46.5% | 0.7× |
| Q3 FY09 | 31 Jan 2009 | -1.8% | +1.8% | -10.4% | 0.2× |
| Q2 FY09 | 27 Oct 2008 | -10.1% | +6.5% | -18.3% | 1.0× |
| Q1 FY09 | 30 Jul 2008 | -2.4% | -3.2% | -16.8% | 1.0× |
| Q3 FY08 | 1 Feb 2008 | +2.6% | -1.7% | -8.1% | 0.4× |
| Q4 FY07 | 1 Jul 2007 | -0.4% | +3.7% | -6.0% | 3.0× |
| Average | -0.2% | +0.2% | +3.2% | ||
Close-to-close from the session before the filing could trade. Day 0 is the first session after it.
Growth · Q1 FY27
CSVRevenue YoY+13.9%
Profit YoY-10.0%
Interest cost YoY+15.7%
Revenue QoQ-34.2%
Profit QoQ-64.5%
| CAGR | 2Y | 3Y | 4Y | 5Y | 6Y | 7Y |
|---|---|---|---|---|---|---|
| Revenue | +4.8% | +9.0% | +7.3% | +9.4% | +10.0% | — |
| Profit | -35.1% | +3.7% | -20.4% | -14.2% | -3.5% | — |
Key data
CSVOpen268.70
Day range265.00 – 274.70
52-week range107.00 – 295.83
From 52w high-8.9%
RSI (14)57.6
ATR (14)15.86
Volume3.60L
Avg volume (20D)23.66L
Rel volume0.15×
Volatility (1Y)49.8%
Turnover₹9.7Cr
SMA 50 / 200224.46 / 172.68
Delivery percentage
Latest · 6 Oct 202635.8%
20-day avg33.3%
1-year avg58.8%
Percentile (own history)11th
Range6.4–100.0%
Sessions1,731
Over the last 20 sessions KOPRAN settled 33.3% of its traded quantity, which is ordinary for an NSE equity. Its one-year average is 58.8%, so recent sessions are running 25.4 points lower than usual. The latest session ranks higher than 11% of the 1,731 sessions on record for it.
What delivery percentage measuresScan the whole market on delivery
IndustryPharmaceuticals
Performance returns
CSV| 1D | 1W | 1M | 3M | 6M | 1Y | |
|---|---|---|---|---|---|---|
| Price | +0.33% | -3.01% | +16.09% | +42.35% | +124.70% | +55.22% |
Valuation
CSVMarket cap₹1,303 Cr
P/E (TTM)52.2
EPS (TTM)5.17
Shares outstanding4.83Cr
Listed9 Jun 1999
Ownership
CSVPromoter44.42%
Promoter Δ QoQ0.00 pp
Public55.58%
FII0.51%
DII0.00%
Pledged0.00%
Quarterly results · consolidated
CSV| Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 | |
|---|---|---|---|---|
| Revenue (₹ Cr) | 117.9 | 194.3 | 234.0 | 154.0 |
| YoY chg | -22.2% | +16.9% | +35.8% | +13.9% |
| Net profit (₹ Cr) | (9.9) | 9.3 | 18.9 | 6.7 |
| YoY chg | -234.4% | -10.2% | +94.9% | -10.0% |
| Net margin | -8.4% | 4.8% | 8.1% | 4.4% |
| EPS | -2.06 | 1.93 | 3.91 | 1.39 |
Shareholding over time
CSVBy quarter
30 Jun 2026 · promoter 44.42% · public 55.58%2021-092026-06
- Promoter
- Public and others
- Promoter
- 44.42%
- Public
- 55.58%
- Promoter change
- 0.00 pp
- Filed
- 9 Jul 2026
- FII
- 0.51%
- DII
- 0.00%
- Promoter pledged
- 0.00%
Promoter and public shares of total equity, from the pattern filed each quarter. Institutional and pledge figures come from a separate filing stage whose backfill is still running, so they are absent for almost every instrument rather than zero.
Financials · quarterly statement
CSV₹ crore, as filed
| Q2 FY24 | Q3 FY24 | Q4 FY24A | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25A | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26A | Q1 FY27 | Trend | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue from operations | 152.6 | 158.9 | 186.1 | 139.4 | 151.6 | 166.2 | 172.4 | 135.2 | 117.9 | 194.3 | 234.0 | 154.0 | |
| Other income | 0.1 | 2.4 | 9.7 | 2.6 | 1.0 | 0.2 | 3.3 | 2.6 | 0.0 | 0.1 | 0.1 | 2.1 | |
| Total income | 152.7 | 161.3 | 195.7 | 142.1 | 152.6 | 166.4 | 175.6 | 137.8 | 117.9 | 194.3 | 234.1 | 156.0 | |
| Total expenses | 134.5 | 140.8 | 170.6 | 127.3 | 142.9 | 152.6 | 161.9 | 127.9 | 129.6 | 183.6 | 208.8 | 147.2 | |
| └ Finance costs | 1.9 | 2.2 | 2.6 | 2.2 | 2.2 | 2.2 | 2.8 | 2.5 | 2.1 | 2.7 | 3.2 | 3.3 | |
| └ Depreciation | 2.8 | 3.3 | 3.6 | 3.9 | 3.9 | 4.0 | 3.9 | 4.3 | 4.3 | 4.4 | 4.5 | 5.8 | |
| Profit before tax | 18.3 | 20.5 | 25.2 | 14.7 | 9.6 | 13.9 | 13.7 | 9.9 | (11.6) | 10.7 | 25.3 | 8.8 | |
| Tax expense | 4.5 | 4.7 | 6.6 | 3.6 | 2.3 | 3.5 | 4.0 | 2.4 | (1.7) | 1.4 | 6.5 | 2.1 | |
| Net profit | 13.8 | 15.8 | 18.6 | 11.1 | 7.4 | 10.4 | 9.7 | 7.4 | (9.9) | 9.3 | 18.9 | 6.7 | |
| EPS | 2.86 | 3.28 | 3.86 | 2.30 | 1.53 | 0.00 | 2.01 | 1.54 | -2.06 | 1.93 | 3.91 | 1.39 | |
| Net margin | 9.02% | 9.94% | 10.01% | 7.96% | 4.87% | 6.25% | 5.61% | 5.51% | -8.42% | 4.81% | 8.06% | 4.35% | |
| PBT margin | 11.96% | 12.90% | 13.53% | 10.57% | 6.36% | 8.34% | 7.96% | 7.31% | -9.86% | 5.53% | 10.83% | 5.72% | |
| Tax rate | 24.55% | 22.99% | 26.04% | 24.69% | 23.44% | 24.99% | 29.42% | 24.67% | — | 13.08% | 25.58% | 23.88% |
A audited · R restated by a later filing · negatives in parentheses. EPS and the share count are restated onto the same split-adjusted basis as the price chart, so they can be read against it; every rupee figure is exactly as filed. A quarterly filing carries a profit and loss only — there is no balance sheet behind it, and so no debt, cash flow or return-on-capital figure here. Latest filed 7 Aug 2026.
KOPRAN at a glance
- KOPRAN closed at ₹269.6 on 6 Oct 2026, +0.33% on the day, +55.2% over one year, 8.9% below its 52-week high of ₹295.83.
- Delivery was 35.8% of traded quantity on 6 Oct 2026, the 11th percentile of its own 1,731 sessions with a reading (20-session average 33.3%, 1-year average 58.8%).
- Market capitalisation is ₹1,303 crore at a trailing P/E of 52.2 (trailing EPS ₹5.17).
- Q1 FY27 results (consolidated, filed 7 Aug 2026): revenue ₹154 crore (+13.9% year on year), net profit ₹7 crore (-10.0%); the price moved -5.0% on the first session after.
- Promoters held 44.42% at 30 Jun 2026, unchanged on the previous filing.
- Q2 FY27 results are expected between 28 Oct 2026 and 13 Nov 2026, going by past filing dates — an estimate, not an announcement.
About
CSVMacro sectorHealthcare
Basic industryPharmaceuticals
ISININE082A01010
SeriesEQ
Listed9 Jun 1999
History from13 Jan 1995
Sessions7,784
Turnover rank#417
Prices are adjusted for splits and bonuses. Delivery figures come from NSE’s daily reports and are unavailable for older sessions. Sourced from the eod2 dataset, last updated 6 Oct 2026.
More in Pharmaceuticals & Biotechnology
CSV- DIVISLABDivi's Laboratories Limited9,550.00+3.85%
- LAURUSLABSLaurus Labs Limited2,050.00+3.99%
- SUNPHARMASun Pharmaceutical Industries Limited1,804.10+1.37%
- WOCKPHARMAWockhardt Limited2,176.40+5.47%
- DRREDDYDr. Reddy's Laboratories Limited1,208.00+0.42%
- MOREPENLABMorepen Laboratories Limited143.96+6.41%
- ZYDUSLIFEZydus Lifesciences Limited1,159.50+1.80%
- SYMBIOTECSYMBIOTEC1,149.50-1.73%
- TORNTPHARMTorrent Pharmaceuticals Limited4,772.000.00%
- GLANDGland Pharma Limited3,006.10+3.25%
- LUPINLupin Limited2,029.30+0.91%
- AUROPHARMAAurobindo Pharma Limited1,692.80+1.07%
All Pharmaceuticals & Biotechnology stocks on the NSEAll Healthcare stocks on the NSE